Displaying drugs 13751 - 13775 of 14619 in total
MF268
Experimental
6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
Experimental
2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
Experimental
Benzylfentanyl
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and ... CD-10* or TOP** peptidases, such as prostate cancer, colorectal cancer, melanoma, pancreatic cancer and …
OMS-103HP
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
OSI-461
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
CX157
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and …
Ulixertinib
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
Serabelisib
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and …
ABT-072
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and …
2X-121
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and …
Londamocitinib
Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high Dose ICS-LABA).
Investigational
Matched Description: … Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and …
Pyrithiamine Pyrophosphate
Experimental
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
Displaying drugs 13751 - 13775 of 14619 in total